Literature DB >> 8535054

The role of the immune system in anti-tumour responses. Potential for drug therapy.

S Dermime1, J Barrett, C Gambacorti-Passerini.   

Abstract

In the last 5 years significant progress has been made in our understanding of the molecular nature of anti-tumour T cell-mediated responses. This review describes the involvement of the cellular immune system in the recognition and destruction of cancer cells. Four aspects are discussed: (i) the generalized immune activation induced by the systemic administration of cytokines, in particular, interleukin-2; (ii) the specific T cell-mediated reactions against tumour cells through the recognition of tumour-associated molecules, 1) and tyrosinase proteins described in melanomas, and minor histocompatibility antigens in the setting of allogenic bone marrow transplantation for leukaemia; (iii) the potentially significant but still hypothetical immune-mediated recognition of molecules either tumour-associated or transformation-related (including altered oncogenic proteins); and (iv) the role of co-stimulatory molecules in the induction of tumour-specific immunity. The current and future therapeutic applications in cancer treatment and potential limitations in this approach are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8535054     DOI: 10.2165/00002512-199507040-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  146 in total

Review 1.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity.

Authors:  E C Guinan; J G Gribben; V A Boussiotis; G J Freeman; L M Nadler
Journal:  Blood       Date:  1994-11-15       Impact factor: 22.113

2.  Source of unique tumour antigens.

Authors:  A Townsend; C Ohlén; M Rogers; J Edwards; S Mukherjee; J Bastin
Journal:  Nature       Date:  1994-10-20       Impact factor: 49.962

3.  Thyroid dysfunction associated with immunotherapy for patients with cancer.

Authors:  D J Schwartzentruber; D E White; M H Zweig; B D Weintraub; S A Rosenberg
Journal:  Cancer       Date:  1991-12-01       Impact factor: 6.860

4.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

5.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

6.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

Authors:  R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

7.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

Authors:  S C Saris; S A Rosenberg; R B Friedman; J T Rubin; D Barba; E H Oldfield
Journal:  J Neurosurg       Date:  1988-07       Impact factor: 5.115

Review 8.  Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens.

Authors:  C Gambacorti-Passerini
Journal:  Int J Clin Lab Res       Date:  1993

9.  The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.

Authors:  S Vijayasaradhi; B Bouchard; A N Houghton
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  P G Coulie; V Brichard; A Van Pel; T Wölfel; J Schneider; C Traversari; S Mattei; E De Plaen; C Lurquin; J P Szikora; J C Renauld; T Boon
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  1 in total

1.  Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.

Authors:  Shane C Burgess; T Fred Davison
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.